Back to News
Market Impact: 0.48

Canaccord raises USA Rare Earth stock price target on acquisition

AAPLUSARSMCIAPP
Analyst EstimatesAnalyst InsightsM&A & RestructuringCompany FundamentalsCommodities & Raw MaterialsInfrastructure & DefenseManagement & Governance
Canaccord raises USA Rare Earth stock price target on acquisition

Canaccord raised its price target on USA Rare Earth to $32 from $29 while keeping a Buy rating, citing the Serra Verde acquisition as a step toward positive EBITDA and a stronger Western rare earth supply chain. The company now has a 15-year off-take agreement covering 100% of Serra Verde’s Phase 1 output, which Canaccord says could generate $346 million or more in annual revenue. The stock is up 32.9% in the past week and 89.75% year to date, though InvestingPro flags the shares as overvalued given $46.3 million in trailing twelve-month negative EBITDA.

Analysis

USAR is moving from a single-project story to a vertically integrated supply-chain option on Western rare-earth independence. The market is likely underpricing the value of control over oxide feedstock because the bottleneck is no longer mining capacity but separation, metallization, and qualification — the parts that create real scarcity rents and customer lock-in. If management can convert the announced contract into bankable, repeatable offtake, the asset base starts to look less like a cyclical miner and more like a strategic infrastructure platform with pricing power. The second-order effect is pressure on incumbent non-Chinese processors and magnet makers: once a credible Western merchant supplier exists, OEMs can dual-source qualification and use USAR as leverage against Asian suppliers, potentially compressing margins across the supply chain. That said, the financing and integration burden is enormous; the equity is effectively underwriting a multi-year execution sequence before EBITDA inflects. The market is rewarding geopolitical optionality today, but the risk is that dilution, permitting friction, or customer qualification delays push the cash-flow crossover out by 12-24 months. The consensus is treating the contract announcement as de-risking, but the real issue is whether the company can deliver separated oxides at industrial yield and consistent purity, not whether the headline revenue number exists on paper. The stock’s move already discounts a lot of “strategic asset” language, so upside from here likely requires either a materially faster EBITDA path or additional government-backed funding. Near term, this can keep squeezing shorts, but over a 3-6 month horizon the name may start trading more on capital structure risk than geopolitical narrative.